| BIOA |
BioAge Labs, Inc. |
85%
|
Reciprocal relationship from BIOA graph: royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized under the Novartis Agreement in the three m… |
| GLUE |
Monte Rosa Therapeutics, Inc. |
85%
|
Reciprocal relationship from GLUE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: pany has identified certain performance obligations within the agreement as… |
| RGNX |
REGENXBIO Inc. |
85%
|
Reciprocal relationship from RGNX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from RGNX graph: . (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Nova… |
| BNBX |
BNB Plus Corp. |
72%
|
Reciprocal relationship from BNBX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNBX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNBX… |
| CRNX |
Crinetics Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from CRNX graph: products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement … |
| CTMX |
CytomX Therapeutics, Inc. |
72%
|
Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX… |
| CYTK |
Cytokinetics, Incorporated |
72%
|
Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subse… |
| GKOS |
Glaukos Corporation |
72%
|
Reciprocal relationship from GKOS graph: compete with many companies, including divisions of companies much larger than us that may have greater resources and name recognition, and smaller companies … |
| IMNM |
Immunome, Inc. |
72%
|
Reciprocal relationship from IMNM graph: third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement a… |
| INCY |
Incyte Corporation |
72%
|
Reciprocal relationship from INCY graph: (in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ … |
| IRIX |
IRIDEX Corporation |
72%
|
Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, … |
| KMDA |
Kamada Ltd. |
72%
|
Reciprocal relationship from KMDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: sell products in the Distribution segment in Israel, we must register the p… |
| LEGN |
Legend Biotech Corporation |
72%
|
Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN… |
| LNTH |
Lantheus Holdings, Inc. |
72%
|
Reciprocal relationship from LNTH graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LNTH graph: ncreasingly competitive environment in which other PSMA PET imaging agents … |
| LQDA |
Liquidia Corporation |
72%
|
Reciprocal relationship from LQDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, includi… |
| MLTX |
MoonLake Immunotherapeutics |
72%
|
Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to e… |
| PLRX |
Pliant Therapeutics, Inc. |
72%
|
Reciprocal relationship from PLRX graph: pearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the … |
| PTCT |
PTC Therapeutics, Inc. |
72%
|
Reciprocal relationship from PTCT graph: nion of the CHMP of the EMA to not renew the authorization of Translarna for the treatment of nmDMD. This change in estimate for sales allowance resulted in a… |
| RDY |
Dr. Reddy's Laboratories Limited |
72%
|
Reciprocal relationship from RDY graph: ell lung cancer following the results of the futility analysis. As a result, the Company recorded an impairment loss of Rs. 914 (U.S.$ 10 ) in the consolidated… |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from REGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from REGN… |
| SDGR |
Schrödinger, Inc. |
72%
|
Reciprocal relationship from SDGR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from SDGR… |
| SLGL |
Sol-Gel Technologies Ltd. |
72%
|
Reciprocal relationship from SLGL graph: se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cove… |
| TCRX |
TScan Therapeutics, Inc. |
72%
|
Reciprocal relationship from TCRX graph: ver $ million, based upon the achievement of certain clinical development and commercial milestones, as well as tiered single-digit royalty payments on net sa… |
| TGTX |
TG Therapeutics, Inc. |
72%
|
Reciprocal relationship from TGTX graph: all rights under the Commercialization Agreement for a period of two years in the event of a change in control of TG. 13 Table of Contents TG-1701 (BTK inhi… |
| VOR |
Vor Biopharma Inc. |
72%
|
Reciprocal relationship from VOR graph: lth authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. Any… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
Reciprocal relationship from VYGR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VYGR… |
| XNCR |
Xencor, Inc. |
72%
|
Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of Decemb… |
| ZBIO |
Zenas BioPharma, Inc. |
72%
|
Reciprocal relationship from ZBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug su… |
| ZVRA |
Zevra Therapeutics, Inc. |
72%
|
Reciprocal relationship from ZVRA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmfu… |
